Update with Aeolus Pharmaceuticals, Inc. – Biodefense and Biotechnology Company Discusses Clinical Development and Milestones for 2016-2017
You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of novel compounds, known as metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies. For more information, please visit Aeolus's corporate website at www.aolsrx.com.
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stocknewsnowcom-publishes-new-snnlive-video-interview-with-aeolus-pharmaceuticals-inc-discussing-clinical-development-and-milestones-for-2016-2017-300295258.html